导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.13% | 1271/4773 |
| 近一周 | -2.60% | 2638/5462 |
| 近一月 | -5.10% | 3060/5421 |
| 近一季 | -5.96% | 1952/5209 |
| 近半年 | -4.92% | 2669/4920 |
| 近一年 | 8.59% | 1174/4366 |
| 近两年 | 71.96% | 941/2954 |
| 近三年 | 32.42% | 952/2253 |
| 成立以来 | 57.17% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.43% 940/4961 |
14.88% 1746/5312 |
- - |
- - |
| 2025 | 31.37% 1241/4813 |
3.11% 1189/3635 |
3.89% 923/4076 |
19.97% 2065/4524 |
2.23% 1036/4813 |
| 2024 | 1.40% 2016/3463 |
-6.62% 2070/2808 |
-3.20% 1320/3014 |
12.51% 2327/3129 |
-0.29% 1372/3463 |
| 2023 | -4.93% 706/2656 |
8.18% 487/2280 |
-5.09% 1366/2385 |
-3.53% 947/2515 |
-4.01% 844/2655 |
| 2022 | -23.75% 1165/2207 |
-14.32% 935/1919 |
3.56% 1133/2016 |
-10.36% 387/2113 |
-4.14% 1884/2208 |
| 2021 | 20.85% 174/1822 |
-0.36% 359/1255 |
9.30% 566/1330 |
6.73% 212/1466 |
3.97% 377/1822 |
| 2020 | - - |
- - |
24.66% 166/1067 |
8.01% 743/1164 |
5.85% 770/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 海富通中证500增强C VS. 长安沪深300非周期A(740101) |